Table 4: 10 recurrent stroke cases with NOACs and 7 recurrent stroke cases with VKA.
NOACs: Non-vitamin K Antagonist Oral Anticoagulants,VKA: vitamin K antagonists, warfarin, mRS: Modified Rankin Scale, DA: Dabigatran, RI: Rivaroxaban, AP: Apixaban, Re: recurrent, 1st: First Event Type of stroke: CE: Cardioembolic Stroke, AT: Atherothrombotic Brain Infarction, TIA: Transient Ischemic Attack, CH: Cerebral Hemorrhage*p<0.05
| Case | Age | Initial amount of NOACs | Type of stroke | Swithched NOACs | Stroke volume(cm3) | Discharge mRS | Micrbleeds on MRI | hemorrhagic infarction |
NOACs group(n=10) | 1 | 67 | DA 300mg | CERe | DA 300mg | 0.48 | 1 | none | none |
2 | 71 | DA 220mg | ATRe | DA 300mg | 0.32 | 0 | none | none |
3 | 67 | RI 15mg | CE1st | DA 300mg | 1.16 | 2 | none | none |
4 | 86 | RI 10mg | CERe | RI 10mg | 15.95 | 1 | none | none |
5 | 74 | RI 10mg | CE1st | DA 220mg | 0.05 | 3 | none | none |
6 | 89 | RI 10mg | ATRe | API 5mg | 0.07 | 0 | none | none |
7 | 72 | RI 15mg | CERe | API 10mg | 1.27 | 2 | none | none |
8 | 80 | API 5mg | TIA | API 5mg | 0 | 0 | none | none |
9 | 92 | DA 220mg | CERe | API 5mg | 7.69 | 4 | none | none |
10 | 78 | DA 220mg | CERe | RI 10mg | 6.71 | 4 | positive | positive |
| mean | 78.6(9.1) | | | | 3.37(5.25)* | 1.7(1.5)* | | |
VKA group(n=7) | 1 | 82 | | CERe | RI 10mg | 24.84 | 5 | none | none |
2 | 71 | | CERe | DA 300mg | 1.22 | 0 | none | none |
3 | 82 | | CERe | RI 10mg | 62.65 | 4 | none | none |
4 | 81 | | CERe | RI 10mg | 12.77 | 5 | none | none |
5 | 90 | | CERe | API 5mg | 59.09 | 4 | none | none |
6 | 83 | | CERe | RI 15mg | 3.28 | 4 | positive | positive |
7 | 88 | | CERe | API 5mg | 28.07 | 4 | none | none |
| mean | 82.4(6.1) | | | | 27.42(24.95)* | 3.7(1.7)* | | |